← Leaderboards
Stephen Joseph Balevic
Duke University
$829,603
Attributed
$829,603
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $166.1K · FY2020–24$200K$150K$100K$50K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$829,603 · 1
By mechanism
K23$829,603 · 1
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Farshid Guilak$32,330,672
- Kenneth G. Manton$25,808,973
- Francis Joseph McClernon$15,864,633
- Kyle D Allen$11,781,402
- Debra Silver$15,197,188
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultAdult ObesityAffectAgreementApplications GrantsArthritisBiologicalBiological MarkersBiological ProductsBloodCareerCareer DevelopmentChildChildhoodChronic Childhood ArthritisClinicClinical PharmacologyClinical ResearchClinical TrialsCollaborationsConduct Clinical TrialsCytokineDatabasesDesign
Grant awards (5)
Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis$166,104
K23 · FY2024 · AR · contact PI
Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis$166,104
K23 · FY2023 · AR · contact PI
Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis$166,104
K23 · FY2022 · AR · contact PI
Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis$165,187
K23 · FY2021 · AR · contact PI
Optimal Dosing for Biologic Agents in Obese Patients with Rheumatoid and Juvenile Arthritis$166,104
K23 · FY2020 · AR · contact PI